Sartorius Stedim Biotech is recording significant growth in 2025

Sartorius Stedim Biotech reported solid performance for 2025, with preliminary unaudited revenue reaching €2,967 million, representing a 9.6% increase at constant exchange rates. Current EBITDA rose 17.3% to €914 million, resulting in a margin of 30.8%. Net income jumped 26.7% to €428 million.

This performance is primarily attributed to the growth in recurring consumables-related activities, while equipment sales showed signs of stabilization. All regions contributed to this growth, with a notable increase of 11.8% in the Americas region.

For 2026, the company expects growth of 6 to 10% at constant exchange rates, focusing more on innovation and customer needs.